目的 探讨阳离子转运蛋白1（SLC22A1）基因在肝细胞癌中的表达情况和预后意义。方法 用The Human Protein Atlas（HAP）数据库分析SLC22A1蛋白在肝细胞癌中的表达情况。利用Oncomine和GEPIA数据库分析SLC22A1基因在肝细胞癌和肝正常组织中的表达水平。利用GEPIA和Linked Omics数据库分析SLC22A1基因与肝细胞癌患者临床相关性：总生存期（OS）、无瘤生存期（DFS）、病理分期和种族。采用Metascape在线工具对SLC22A1相关基因进行功能和通路富集分析。结果 LC22A1蛋白和mRNA在肝细胞癌组织中显著低于正常组织，且与肝细胞癌预后呈正相关（P<0.001）。肝细胞癌中SLC22A1基因表达水平与预后、病理分期存在显著差异性（P<0.05），与种族无相关性。功能富集分析显示，SLC22A1基因通过影响小分子分解代谢过程、对异源生物刺激的反应和有机酸生物合成过程等发挥作用。通路富集分析显示，SLC22A1基因通过作用于过氧化物酶体、脂肪酸降解和精氨酸和脯氨酸代谢等通路起作用。结论 细胞癌组织中SLC22A1蛋白和mRNA表达水平均显著低于肝正常组织，其表达情况与肝细胞癌预后存在显著关联，提示SLC22A1可能成为评估肝细胞癌预后的指标和研发肝细胞癌相关靶向药物的候选靶点，为肝细胞癌研究提供新研究思路。

Objective To investigate the expression of cation transporter 1 (SLC22A1) gene and its prognostic significance in hepatocellular carcinoma (HCC). Methods The Human Protein Atlas (HAP) database was used to analyze the expression of SLC22A1 protein in hepatocellular carcinoma. The online tools Oncomine and GEPIA were used to evaluate the expression of SLC22A1 gene in hepatocellular carcinoma. GEPIA and Linked Omics databases were also used to analyze the correlation between COL1A2 and clinical indicators overall survival (OS), tumor-free survival (DFS), pathological stage, and race. Metascape online tools were used to perform functional and pathway enrichment analysis of SLC22A1-related genes. Results SLC22A1 protein and mRNA were highly expressed in normal tissues and was positively correlated with prognosis (P<0.001). The expression levels of SLC22A1 gene in HCC were significantly different from prognosis and pathological stage (P<0.05), and it was not related to race. Functional enrichment analysis showed that the SLC22A1 gene played a role by affecting small molecule catabolic processes, responses to heterologous biological stimuli, and organic acid biosynthesis processes. Pathway enrichment analysis showed that the SLC22A1 gene works through pathways such as peroxisomes, fatty acid degradation, and arginine and proline metabolism. Conclusion SLC22A1 gene and protein is highly expressed in normal tissues, and its expression level is significantly correlated with prognosis, which might be an important therapeutic target and biomarker of HCC.

R979.1